Novartis names GSK executive as new Sandoz CEO by Angus Liu Wednesday, April 24, 2019 Novartis is transforming Sandoz into an autonomous unit within the larger company. And it has tapped a former executive to take the reins.
Zolgensma death clouds Novartis' strong Q1 by Angus Liu Wednesday, April 24, 2019 Cosentyx and Entresto delivered strong growth again, but Novartis CEO Vas Narasimhan took pains to explain a death case in a Zolgensma trial.
U.S. generics players, Chi-Med and more—FiercePharmaAsia by Angus Liu Friday, April 19, 2019 Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.
'Old guard' generics players yield U.S. scripts lead by Angus Liu Thursday, April 18, 2019 Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.
United illegally blocked generics to Remodulin, Sandoz suit says by Eric Sagonowsky Thursday, April 18, 2019 United Therapeutics faces allegations of illegally blocking Remodulin generics by teaming with a devicemaker.
Amid spinoff talk, Novartis generics biz licenses Shionogi brand by Angus Liu Thursday, April 11, 2019 The Novartis unit pivoting toward complex generics and biosims has licensed a newly approved branded med, Shionogi's constipation drug Symproic.
Generics take aim at United's top-selling Remodulin by Eric Sagonowsky Wednesday, March 27, 2019 Sandoz launched a generic to United Therapeutics' Remodulin, which pulled in about $500 million in the U.S. last year.
4. Novartis by Angus Liu To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Novartis' Sandoz chief fuels spinoff talk with unexpected exit by Angus Liu Thursday, March 14, 2019 Sandoz head Richard Francis said he can't commit to what CEO Vas Narasimhan calls "a multiyear transformation program" for the generics unit.
Sandoz SXSW hackathon names 3 winners by Beth Snyder Bulik Wednesday, March 13, 2019 At South by Southwest, Novartis' Sandoz hackathon judges were so impressed by the finalists that they named three winners instead of the planned one.
